NanoViricides, Inc. (Pink Sheets:NNVC), today (8:00)announced that it has commenced preclinical studies for its anti-viral drug FluCide-I(TM). The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, under the direction of Dr. Krishna Menon. Dr. Menon, the Company's Chief Regulatory Officer, explained that nanoviricides are complex materials. "We have started working on the basic safety of the polymer under a maximum tolerated dose protocol in mice. In the second part we will study the ligands that target FluCide-I(TM) to H5N1 and common influenza viruses. Thereafter, we will study the efficacy of FluCide-I(TM) itself against H5N1 and common influenza."
Dr. Anil Diwan, President, explained that, "if successful, the relevance of nanoviricides can be compared to the discovery of Penicillin, the very first bactericide. Prior to antibiotics, bacterial infections were treated with patient isolation, chicken soup and Vitamin C. Current anti-viral medicines can at best only partially inhibit the virus from multiplying in the human body. Although we cannot make claims of certainty yet, after we get good results from these studies we will be able to say that we have developed a true virus killer."
The Company is encouraged by the recent statements from high level international officials and health ministers of different countries concerning the urgency of developing effective vaccines and treatments and believes that a rapid regulatory approval of FluCide-I(TM), is possible should these studies be successful.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
Contact Information: NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo*nanoviricides.com
Stock is already up .10 (20%) at noon. I bought this back when it was at .18. Enjoying the ride and holding for the long haul, this company is coming up with the next penicillin!!
Posted by greatimes on :
Just keeps going up.
Posted by jdg257 on :
just hit .99 today! this thing just keeps climbing like crazy, bought this at .18!!
Posted by vg on :
NanoViricides Reports Initial Safety Results Regarding its Anti-Influenza and Bird Flu Drug
By BusinessWire Last Update: 11/7/2005 8:00:16 AM Data provided by
WEST HAVEN, Conn., Nov 07, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced that it has completed its initial safety studies on the major constituent of its anti-viral drug, FluCide-I(TM). The polymer which is unique and proprietary to NanoViricides, has been effectively tested for any toxic symptoms or for any ill effects in laboratory animals. The preliminary results were successful. More studies are being conducted for further detailed evaluations. The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School.
The Company will follow these studies with preliminary pre-clinical evaluations of certain ligands designed to specifically target the drug to H5N1 (avian flu) as well as common influenza viruses.
The Company's management has deemed this drug development project as its most urgent priority and believes that should FluCide-I(TM) prove successful in pre-clinicals, the timeline for regulatory approval in the later phases can be significantly shortened. The Company is encouraged by reports in Saturday's Wall St. Journal that the "FDA's acting head said that he is assembling a team of agency experts who will work to approve both antivirals and vaccines that would treat a pandemic flu virus."
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for anti-viral therapy. A nanoviricide(TM) is a specially designed, flexible, nanomaterial with or without an encapsulated active pharmaceutical ingredient and a targeting ligand to a specific type of virus, like a guided missile.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
Posted by marcinek on :
quote:Originally posted by jdg257: just hit .99 today! this thing just keeps climbing like crazy, bought this at .18!!
How did you find out about it back then? Did you see it on a board or did you find it yourself? If you did it yourself, how did you stumble upon it?
Posted by ItsOnlyMoney84 on :
Is it too late to buy this stock for a gain??? Any new info ...